{"id":"standard-buprenorphine-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Sleep disturbances"},{"rate":"5-10%","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL2368861","moleculeType":"Small molecule","molecularWeight":"504.11"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the mu-opioid receptor, buprenorphine activates the receptor, but to a lesser extent than full agonists like morphine. This partial agonism reduces the risk of overdose and dependence, while still providing therapeutic benefits.","oneSentence":"Buprenorphine acts as a partial agonist at the mu-opioid receptor, providing pain relief and reducing withdrawal symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:04.521Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of opioid use disorder"},{"name":"Pain relief in moderate to severe pain"}]},"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT06367387","phase":"PHASE4","title":"Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erin Winstanley","startDate":"2024-05-28","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":268},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT06005662","phase":"PHASE2","title":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2027-04","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT04771689","phase":"PHASE4","title":"Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-07-01","conditions":"Post-operative Pain","enrollment":""},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT04091009","phase":"PHASE4","title":"Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-10","conditions":"Opioid-use Disorder, Opioid Use Disorder, Mild","enrollment":""},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT04345718","phase":"PHASE2, PHASE3","title":"EXHIT ENTRE Comparative Effectiveness Trial","status":"COMPLETED","sponsor":"Gavin Bart","startDate":"2021-08-09","conditions":"Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":344},{"nctId":"NCT06316830","phase":"PHASE2, PHASE3","title":"Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose","status":"RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2025-01-06","conditions":"Opioid Use Disorder","enrollment":250},{"nctId":"NCT05589181","phase":"PHASE3","title":"High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-04-06","conditions":"Opioid Use Disorder","enrollment":140},{"nctId":"NCT05450718","phase":"PHASE4","title":"Low-dose Buprenorphine Initiation for Opioid Use Disorder","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-11-11","conditions":"Opioid Use Disorder","enrollment":70},{"nctId":"NCT06379984","phase":"PHASE2","title":"Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-05-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT05528848","phase":"PHASE1","title":"Multi-System Analysis of Opioid Receptor Binding","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-09-20","conditions":"Healthy, Opioid Use Disorder","enrollment":60},{"nctId":"NCT06067737","phase":"PHASE2","title":"Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-08","conditions":"Opioid Use Disorder","enrollment":90},{"nctId":"NCT04893525","phase":"PHASE2, PHASE3","title":"Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-07-23","conditions":"Opioid-use Disorder","enrollment":658},{"nctId":"NCT06494904","phase":"PHASE3","title":"Standard Versus High Dose ED-Initiated Buprenorphine Induction","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-12-06","conditions":"Opioid Use Disorder","enrollment":360},{"nctId":"NCT06288711","phase":"NA","title":"Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2024-06-03","conditions":"Opioid Use Disorder, Posttraumatic Stress Disorder","enrollment":135},{"nctId":"NCT06406400","phase":"PHASE1","title":"Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-05-13","conditions":"Opioid Use Disorder","enrollment":15},{"nctId":"NCT04060654","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Extension Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-10-21","conditions":"Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate","enrollment":17},{"nctId":"NCT06880718","phase":"PHASE4","title":"Injectable Buprenorphine in Prison: a Preference Trial","status":"NOT_YET_RECRUITING","sponsor":"Lifespan","startDate":"2025-06","conditions":"Opioid Use Disorder, Incarceration, Medications for Opioid Use Disorder","enrollment":60},{"nctId":"NCT04225598","phase":"PHASE2","title":"Emergency Department-Initiated Buprenorphine Validation Network Trial","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-07-08","conditions":"Opioid-use Disorder","enrollment":2000},{"nctId":"NCT06742554","phase":"PHASE4","title":"Comparative Efficacy of Buprenorphine Transdermal Patch Versus Tramadol in Postoperative Analgesia for Shoulder Arthroscopy","status":"ACTIVE_NOT_RECRUITING","sponsor":"medina medical center","startDate":"2024-12-01","conditions":"Postoperative Pain, Shoulder Pain, Opioid Analgesia","enrollment":70},{"nctId":"NCT03605342","phase":"PHASE2","title":"Optimal Treatment of Veterans With PTSD and Comorbid OUD","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-10-01","conditions":"Post-Traumatic Stress Disorders, Opiate Use Disorder","enrollment":38},{"nctId":"NCT04234191","phase":"PHASE2","title":"Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-08-18","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT04794790","phase":"EARLY_PHASE1","title":"Buprenorphine Induction for Fentanyl Dependent Opioid Users","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-05-09","conditions":"Opioid Dependence Fentanyl","enrollment":""},{"nctId":"NCT04762537","phase":"NA","title":"Surmounting Withdrawal to Initiate Fast Treatment With Naltrexone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2021-03-16","conditions":"Opioid-use Disorder","enrollment":415},{"nctId":"NCT03026790","phase":"PHASE2","title":"Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2017-10-19","conditions":"Chronic Pain","enrollment":820},{"nctId":"NCT04240093","phase":"NA","title":"CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder","status":"COMPLETED","sponsor":"Brown University","startDate":"2019-11-15","conditions":"Opioid-use Disorder, Medication Adherence, Health Care Utilization","enrollment":44},{"nctId":"NCT04464512","phase":"PHASE4","title":"Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2020-01-10","conditions":"Addiction Opiate, Chronic Pain, Fractures, Bone","enrollment":""},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT01843023","phase":"PHASE4","title":"Extended Release Naltrexone for Opioid-Dependent Youth","status":"COMPLETED","sponsor":"Friends Research Institute, Inc.","startDate":"2013-06","conditions":"Drug Dependence","enrollment":288},{"nctId":"NCT04850664","phase":"PHASE2","title":"Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder","status":"UNKNOWN","sponsor":"Evon Medics LLC","startDate":"2021-03-26","conditions":"Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms","enrollment":190},{"nctId":"NCT04162145","phase":"NA","title":"BRIDGE Device for Treatment of Opioid Withdrawal","status":"TERMINATED","sponsor":"BrightView LLC","startDate":"2019-11-15","conditions":"Opioid Withdrawal, Pain, Craving","enrollment":12},{"nctId":"NCT02496403","phase":"NA","title":"Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2015-12","conditions":"Opiate Substitution Treatment","enrollment":239},{"nctId":"NCT03254459","phase":"PHASE2","title":"Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain","status":"COMPLETED","sponsor":"INSYS Therapeutics Inc","startDate":"2017-09-12","conditions":"Pain, Postoperative","enrollment":100},{"nctId":"NCT01717963","phase":"PHASE3","title":"Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway","status":"COMPLETED","sponsor":"University of Oslo","startDate":"2012-10","conditions":"Opioid Dependence","enrollment":166},{"nctId":"NCT03266445","phase":"PHASE4","title":"Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2018-10-05","conditions":"Opioid-use Disorder, Pain, Acute, Surgery","enrollment":76},{"nctId":"NCT01377610","phase":"PHASE1","title":"Improved Strategies for Outpatient Opioid Detoxification","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-06","conditions":"Opioid Dependence","enrollment":150},{"nctId":"NCT00941304","phase":"PHASE2","title":"Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain","status":"COMPLETED","sponsor":"BioDelivery Sciences International","startDate":"2009-08","conditions":"Dental Pain","enrollment":153},{"nctId":"NCT01560221","phase":"PHASE1","title":"Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-10","conditions":"Substance-related Disorders, HIV Risk Behavior","enrollment":38},{"nctId":"NCT00324038","phase":"PHASE4","title":"Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly","status":"COMPLETED","sponsor":"Napp Pharmaceuticals Limited","startDate":"2006-03","conditions":"Osteoarthritis","enrollment":219}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard Buprenorphine Dose","genericName":"Standard Buprenorphine Dose","companyName":"Rutgers, The State University of New Jersey","companyId":"rutgers-the-state-university-of-new-jersey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a small molecule that acts as a mu opioid receptor agonist, classified as an agonist. It is used to treat conditions such as Opiate Use Disorder, Opioid Use Disorder, and Post-Traumatic Stress Disorders, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}